Enlivex Therapeutics Ltd.
ENLV
|
News
|
$1.52
15.15%
13.16%
130K
|
Health Technology
(0.0% 1d) (-67.9% 1m) (-52.7% 1y) (0.0% 2d) (3.9% 3d) (-5.7% 7d) (160.87% volume)
Earnings Calendar: 2022-11-18
Market Cap: $ 28,220,718
http://www.enlivex.com
Sec Filling | Patents | 77 employees
(IL) Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. It produces treatment devices for CAR-T cancer treatment procedures, Graft-versus-Host disease resulting from bone-marrow transplantations, solid organ transplantations and an assembly of autoimmune and inflammatory conditions, such as Crohn's disease, rheumatoid arthritis, gout, multiple sclerosis and other disorders. The company is headquartered in Nes-Ziona, Israel.
sclerosis cancer autoimmunity israel multiple sclerosis car-t rheumatoid arthritis bone treatment cancer treatments
add to watch list Paper trade email alert is off
Press-releases
Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis
Published: 2024-04-22 (Crawled : 12:00) - globenewswire.com
ENLV | News | $1.52 15.15% 13.16% 130K
|
Health Technology
|
| O: -6.06%
H: 4.84%
C: 2.42%
first osteoarthritis trial
Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis
Published: 2024-04-16 (Crawled : 12:00) - globenewswire.com
ENLV | News | $1.52 15.15% 13.16% 130K
|
Health Technology
|
| O: -12.58%
H: 10.61%
C: 9.85%
osteoarthritis authorization for trial
Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis
Published: 2024-04-11 (Crawled : 19:00) - globenewswire.com
ENLV | News | $1.52 15.15% 13.16% 130K
|
Health Technology
|
| O: 3.28%
H: 2.12%
C: -16.4%
topline trial results
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
Published: 2024-04-11 (Crawled : 12:00) - globenewswire.com
ENLV | News | $1.52 15.15% 13.16% 130K
|
Health Technology
|
| O: -44.19%
H: 1.36%
C: -17.19%
topline trial results
Enlivex Completes Enrollment Of All 120 Patients In Phase 2 Trial Of Allocetra In Patients With Sepsis, Third-Leading Cause Of Mortality In US Hospitals
Published: 2024-02-21 (Crawled : 15:00) - biospace.com/
ENLV | News | $1.52 15.15% 13.16% 130K
|
Health Technology
|
| O: -0.61%
H: 0.62%
C: -0.92%
trial
Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method
Published: 2024-02-07 (Crawled : 13:00) - globenewswire.com
ENLV | News | $1.52 15.15% 13.16% 130K
|
Health Technology
|
| O: 1.55%
H: 4.96%
C: 1.53%
patent
Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis
Published: 2024-01-17 (Crawled : 13:00) - globenewswire.com
ENLV | News | $1.52 15.15% 13.16% 130K
|
Health Technology
|
| O: 1.75%
H: 0.69%
C: -1.37%
osteoarthritis authorization trial
Enlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis
Published: 2023-12-20 (Crawled : 13:00) - globenewswire.com
ENLV | News | $1.52 15.15% 13.16% 130K
|
Health Technology
|
| O: 2.52%
H: 41.1%
C: 19.94%
trial
MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer
Published: 2023-11-21 (Crawled : 12:00) - globenewswire.com
MDWD | $17.54 6.89% 6.44% 48K
|
Health Technology
|
| O: -0.58%
H: 0.0%
C: -1.29%
ENLV | News | $1.52 15.15% 13.16% 130K
|
Health Technology
|
| O: -2.34%
H: 4.19%
C: 4.19%
commercial
Enlivex Announces Reprioritization Plan and Second Quarter 2023 Financial Results
Published: 2023-09-11 (Crawled : 12:00) - globenewswire.com
ENLV | News | $1.52 15.15% 13.16% 130K
|
Health Technology
|
| O: 0.0%
H: 5.45%
C: -12.73%
financial results
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Last 48 Hours Insiders Buying
RKT P 347 | $12.55 -0.63% 0.48% 1.7M
|
Finance
|
22:30
NWFL | News | $24.6 2.03% 1.99% 9.9K
|
Finance
|
22:00
TGEN P 10000 | $0.685 39.71% 6.6K
|
Utilities
|
20:01
MNSB P 310 | $15.88 -2.93% -3.02% 46K
|
Finance
|
15:30
RMCF | $3.54 0.28% 7.1K
|
Consumer Non-Durables
|
20:10